Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619993 | 0.91 | RIPK1 (0.38) | ALDH1A1NPSR1RIPK1NPC1RAB9A | |
| SCHEMBL8990027 | 0.90 | ALDH1A1 (0.36) | ALDH1A1NPSR1NPC1RAB9AMAPT | |
| SCHEMBL9054530 | 0.87 | EPHX2 (0.42) | EPHX2MEN1KMT2A | |
| SCHEMBL9055340 | 0.86 | ALDH1A1 (0.35) | ALDH1A1NPSR1RIPK1FFAR4 | |
| SCHEMBL8988943 | 0.85 | MAPT (0.39) | ALDH1A1RIPK1NPC1RAB9AMAPT | |
| SCHEMBL8989585 | 0.84 | ALDH1A1 (0.35) | ALDH1A1NPSR1RIPK1NPC1RAB9A | |
| SCHEMBL13625662 | 0.84 | MAPT (0.43) | ALDH1A1RIPK1NPC1RAB9AMAPT | |
| SCHEMBL8989588 | 0.83 | EPHX2 (0.39) | EPHX2 | |
| SCHEMBL8988043 | 0.81 | MAPT (0.43) | ALDH1A1RIPK1MAPTKDM4EHPGD | |
| SCHEMBL14523185 | 0.81 | SCN9A (0.43) | ALDH1A1NPC1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2294069-B1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO[3,2,1-IJ]QUINOLINE COMPOUNDS | ALLERGAN INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8431702-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431702-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8309729-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309729-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188279-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188279-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2009137681-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-IJ] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | ALDH1A1 466/4885NPSR1 1233/4885RIPK1 4342/4885 |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | ALDH1A1 466/4885NPSR1 1233/4885RIPK1 4342/4885 |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | ALDH1A1 466/4885NPSR1 1233/4885RIPK1 4342/4885 |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | ALDH1A1 466/4885NPSR1 1233/4885RIPK1 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.